Scout Bio

Philadelphia, United States Founded: 2017 • Age: 9 yrs Acquired By Ceva
Manufacturer of protein therapeutics for animal health
Annual revenue - Latest available
Total funding $29.3M 2 rounds
Employees - Tracked headcount
Investors 7 Known backers
Products 2 Services tracked
Competitors - Brand Intelligence

About Scout Bio

Scout Bio is a company based in Philadelphia (United States) founded in 2017 was acquired by Ceva in January 2024. Scout Bio has raised $29.3 million across 2 funding rounds from investors including Ceva, Frazier Healthcare Partners and Greenspring Associates. Scout Bio offers products and services including AAV Vector Gene Therapy and Therapy for CKD Anemia.

  • Headquarter Philadelphia, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Scout Bio, Inc.
Operational Areas
Healthcare → Veterinary & Animal Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $29.3 M (USD)

    in 2 rounds

  • Latest Funding Round
    $20 M (USD), Series B

    Apr 11, 2019

  • Investors
    Ceva

    & 6 more

  • Employee Count
    Not available
  • Acquired by
    Ceva

    (Jan 25, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Scout Bio

Scout Bio offers a comprehensive portfolio of products and services, including AAV Vector Gene Therapy and Therapy for CKD Anemia.

Product name locked
Category locked
Primary

One-time injection for long-lasting expression of therapeutic proteins in pets

Product name locked
Category locked
Locked

Targets anemia in cats with chronic kidney disease through gene transfer

People of Scout Bio

Headcount 1-10
Employee Profiles 4
Employee Profiles
People
Alex Kau
VP Finance

Unlock access to complete

Funding Insights of Scout Bio

Scout Bio has successfully raised a total of $29.3M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Scout Bio

Scout Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Ceva, Frazier Healthcare Partners and Greenspring Associates.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Investment in animal health innovation is facilitated by Digitalis Ventures.
Locked Locked Locked
-
Locked Locked Locked
Diversified investment management firm
Locked Locked Locked
Premium access

Investor details for Scout Bio

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Scout Bio

Investments
Premium access

Investment portfolio details for Scout Bio

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Scout Bio

Premium access

Detailed financials for Scout Bio

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Scout Bio Comparisons

Scout Bio Primary company
Description
Manufacturer of protein therapeutics for animal health
Location
Philadelphia, United States
Founded Year
2017
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Scout Bio

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Scout Bio

Premium access

Detailed competitors of Scout Bio

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Scout Bio

Premium access

Complete news archive for Scout Bio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Scout Bio

Scout Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Scout Bio is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.

Mark Heffernan is the current CEO of Scout Bio.

Scout Bio is a funded company, having raised a total of $29.3M across 2 funding rounds to date.

Scout Bio was founded in 2017 in Philadelphia, United States, within the biotechnology sector focused on animal health. Gene therapy technologies are developed to address chronic conditions in pets through protein therapeutics. An adeno-associated viral (AAV) vector process is utilized, involving intramuscular injections to enable expression of therapeutic proteins. Operations center on advancing these treatments for veterinary applications.

Scout Bio offers AAV Vector Gene Therapy and Therapy for CKD Anemia.

Scout Bio has 7 investors. Key investors include Ceva, Frazier Healthcare Partners, Greenspring Associates, Digitalis Ventures, and RiverVest Venture Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available